Trade Kiora Pharmaceuticals, Inc. - KPRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.46 |
| Open | 0.45 |
| 1-Year Change | -88.66% |
| Day's Range | 0.45 - 0.48 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 26, 2024 | 0.45 | 0.00 | 0.00% | 0.45 | 0.48 | 0.45 |
| Apr 25, 2024 | 0.46 | 0.00 | 0.00% | 0.46 | 0.46 | 0.45 |
| Apr 24, 2024 | 0.48 | 0.00 | 0.00% | 0.48 | 0.49 | 0.47 |
| Apr 23, 2024 | 0.56 | 0.09 | 19.15% | 0.47 | 0.60 | 0.46 |
| Apr 22, 2024 | 0.46 | 0.00 | 0.00% | 0.46 | 0.46 | 0.43 |
| Apr 19, 2024 | 0.47 | -0.02 | -4.08% | 0.49 | 0.49 | 0.47 |
| Apr 18, 2024 | 0.48 | -0.01 | -2.04% | 0.49 | 0.49 | 0.47 |
| Apr 17, 2024 | 0.48 | -0.04 | -7.69% | 0.52 | 0.52 | 0.48 |
| Apr 16, 2024 | 0.51 | -0.02 | -3.77% | 0.53 | 0.53 | 0.50 |
| Apr 15, 2024 | 0.53 | -0.02 | -3.64% | 0.55 | 0.55 | 0.53 |
| Apr 12, 2024 | 0.55 | -0.02 | -3.51% | 0.57 | 0.58 | 0.53 |
| Apr 11, 2024 | 0.57 | -0.01 | -1.72% | 0.58 | 0.58 | 0.56 |
| Apr 10, 2024 | 0.57 | 0.02 | 3.64% | 0.55 | 0.58 | 0.54 |
| Apr 9, 2024 | 0.54 | -0.03 | -5.26% | 0.57 | 0.58 | 0.50 |
| Apr 8, 2024 | 0.56 | 0.00 | 0.00% | 0.56 | 0.59 | 0.56 |
| Apr 5, 2024 | 0.57 | 0.02 | 3.64% | 0.55 | 0.57 | 0.55 |
| Apr 4, 2024 | 0.55 | -0.02 | -3.51% | 0.57 | 0.58 | 0.55 |
| Apr 3, 2024 | 0.57 | 0.01 | 1.79% | 0.56 | 0.58 | 0.55 |
| Apr 2, 2024 | 0.56 | -0.01 | -1.75% | 0.57 | 0.57 | 0.54 |
| Apr 1, 2024 | 0.58 | -0.09 | -13.43% | 0.67 | 0.67 | 0.57 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kiora Pharmaceuticals, Inc. Company profile
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., formerly Eyegate Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company. The Company is engaged in developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system. The Company's pipeline consists of three assets including KIO-101, KIO-301, and KIO-201 in early to late-stage development for both common and rare eye diseases. KIO-101, is a non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH). Its KIO-301, is a light-sensitive small molecule that acts as a reversible photoswitch, designed to restore the eyes' ability to perceive and interpret light in visually impaired patients. The Company's KIO-201, which is a form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Kiora Pharmaceuticals Inc revenues was not reported. Net loss increased 41% to $8M. Higher net loss reflects Research and Development Expense - Balan increase of 73% to $4.2M (expense), General and Administrative Expense - Bal increase of 26% to $3.5M (expense), Stock-based Compensation in SGA increase of 19% to $453K (expense).
| Industry: | Pharmaceuticals (NEC) |
1371 East 2100 South
Suite 200
SALT LAKE CITY
UTAH 84105
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com